ReviewFrontiers in oncology2025
Research progress on FOXM1 in ovarian cancer diagnosis and therapeutics.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- LINE-1 Deregulation in Ovarian Cancer: Implications for Diagnosis, Prognosis, and Therapeutic Targeting.Molecular diagnosis & therapy · 2026Review
- Mechanisms of Paclitaxel Resistance: Recent Advances and Future Perspectives.International journal of molecular sciences · 2026Review
- The Regulatory Network of FOXM1: Orchestrating Cancer Progression and Resistance to Therapy.International journal of molecular sciences · 2026Review
- Drug resistance in cancer: molecular mechanisms and emerging treatment strategies.Molecular biomedicine · 2025Review
- Metabolomic Investigation of Myelodysplastic Syndromes, Multiple Myeloma, and Homozygous β-Thalassemia.Cells · 2025Review
- HO-1197 as a Multifaceted Therapeutic: Targeting the Cell Cycle, Angiogenesis, Metastasis, and Tumor Immunity in Hepatocellular Carcinoma.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer (OC) is the leading cause of cancer-related death among women, presenting a significant threat to their lives and health. Early-stage OC often lacks distinctive clinical symptoms, leading to most patients being diagnosed at advanced stages. Current treatment strategies primarily involve a combination of surgical resection and chemotherapy, but the therapeutic outcomes are limited, and prognosis remains poor. Therefore, there is a critical need to understand the pathogenesis of OC, identify biomarkers for early diagnosis and prognosis, and discover new therapeutic targets. Forkhead box M1 (FOXM1), recognized as a pro-oncogenic transcription factor (TF), is notably overexpressed in various malignancies, including OC. Research indicates that increased levels of FOXM1 correlate significantly with OC's aggressive behaviors such as proliferation, invasion, migration, epithelial-mesenchymal transition (EMT), and resistance to chemotherapy. These observations suggest that FOXM1 could potentially function as both a biomarker and a therapeutic target, facilitating the early detection and treatment of OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.